ArticleCureus2026
Percutaneous Iatrogenic Atrial Septal Defect Closure Post Transcatheter Mitral Valve Repair: Revisiting MITHRAS Trial in a Larger Cohort.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Transcatheter mitral valve repair (TMVR) creates an iatrogenic atrial septal defect (iASD) that may persist and affect hemodynamics. Although the MITHRAS (Closure of Iatrogenic Atrial Septal Defects Following Transcatheter Mitral Valve Repair) trial showed no benefit of routine closure, its small size and selective population limit generalizability, and observational data remain conflicting. We hypothesized that percutaneous iASD closure (PC-iASD) would be associated with differences in in-hospital clinical and hemodynamic outcomes compared with no closure. Methods Using the National Inpatient Sample (NIS), we evaluated national prevalence, baseline characteristics, and in-hospital outcomes of PC-iASD among patients undergoing TMVR from 2020 to 2022. Results We identified 4,965 weighted TMVR hospitalizations; 431 (8.7%) underwent PC‑iASD closure during the same admission. Compared with TMVR only, the closure cohort had a higher prevalence of pulmonary hypertension (245 (56.9%) vs. 1735 (40.5%), p = 0.0034) and heart failure (411 (95.4%) vs. 3767 (87.9%), p = 0.0396). There were no significant differences in chronic obstructive pulmonary disease, coronary artery disease, end-stage renal disease, or tricuspid regurgitation between the two groups. After multivariate adjustment, there was no difference in in‑hospital mortality, cardiogenic shock, acute heart failure, acute right heart failure, cardiac tamponade, or need for mechanical circulatory support among the two cohorts. Conclusion There have been conflicting results over numerous retrospective and prospective studies regarding the outcomes of post-TMVR iASD closure. Potential benefits of right-sided volume overload may be offset by higher left-atrial pressures after closure. The wide confidence (albeit nonsignificant) toward the development of acute right heart failure, pericardial effusion, and cardiac tamponade raises the possibility of better patient selection or some iASD closure procedural modifications that can help improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.